Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Cellares Plans Bridgewater, New Jersey, Production Operations

01/30/2024
Cellares, an Integrated Development and Manufacturing Organization (IDMO) and cell therapy manufacturing company, plans to establish manufacturing operations in Bridgewater, New Jersey. The project is expected to create 350 jobs in Somerset County.

The 118,000-square-foot manufacturing facility, located at 95 Corporate Drive and formerly occupied by Pfizer, will be capable of producing 40,000 cell therapy batches per year.

“The opening of this facility marks a tremendous milestone towards Cellares’ mission of accelerating access to life-saving cell therapies to meet total global patient demand,” said John Tomtishen, Sr. Vice President and General Manager of the Bridgewater IDMO Smart Factory. “We look forward to partnering with the state and local community to create 350 job opportunities for highly talented individuals as we bring the facility online to manufacture tens of thousands of cell therapy drug products per year.”

Cellares is is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation.

“Not only does Cellares join a thriving life sciences industry here, but they reinforce the fact that many of the cures needed by the world come from Somerset County,” noted Jessica Paolini, Manager of Economic Development for Somerset County. “We are investing in infrastructure critical to the growth and retention of the life sciences, including a recent $3 million investment towards a new training program at Raritan Valley Community College, which will produce the talent needed by cell and gene therapy companies like Cellares.”

Exclusive Research